Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIA study of ITF2357 in JAK2 V617F positive chronic myeloproliferative diseases
2007-004480-21Phase 2Completed
- Sponsor
- Italfarmaco
- Start
- Jan 2008
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of givinostat in polycythemia vera (PV), thrombocythemia, myelofibrosis (MF) and 1 more, sponsored by Italfarmaco. Primary endpoint: Objective response rate. Started Jan 2008; status: completed.
02
Drugs
givinostat
03
Conditions
polycythemia vera (PV)thrombocythemiamyelofibrosis (MF)myeloproliferative disorder (MPD)
Beyond the preview
Go deeper on 2007-004480-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004480-21.